Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000558465 | SCV000627090 | benign | Acute myeloid leukemia | 2024-01-28 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002256341 | SCV002531734 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-12-17 | criteria provided, single submitter | curation | |
St. |
RCV000558465 | SCV002584697 | uncertain significance | Acute myeloid leukemia | 2022-10-04 | criteria provided, single submitter | clinical testing | The CEBPA c.308_313dup (p.Gly103_Gly104dup) change inserts six nucleotides at position 308-313 resulting in an in-frame duplication of two glycine residues. This variant has a maximum subpopulation frequency of 0.17% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/), however data at this position may not be reliable due to mean depth of coverage <30X. This variant has been reported in the literature in an individual with acute myeloid leukemia (PMID: 25468431). In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
Gene |
RCV003235275 | SCV003933044 | uncertain significance | not provided | 2022-12-16 | criteria provided, single submitter | clinical testing | In-frame insertion of 2 amino acids in a repetitive region with no known function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004609425 | SCV005105504 | benign | Inborn genetic diseases | 2024-03-20 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |